CUT-OFF VALUES OF PROSTATE SPECIFIC ANTIGEN DENSITY– AN EFFECTIVE SCREENING MARKER BEFORE PROSTATE BIOPSY

Main Article Content

Zujaja Hina Haroon
Qamar Bashir
Azka Haroon
Usama Bin Khalid

Abstract

OBJECTIVE: To determine cut-off values for prostate specific antigen density (PSAD) in diagnosing prostate carcinoma in symptomatic patients.


METHODS: This cross sectional, observational study conducted at Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan from June 2020 to May 2021. Symptomatic patients (309) having prostatic enlargement on ultrasound were selected through consecutive sampling. All the patients underwent prostate biopsy for histopathological diagnosis. Prostate specific antigen density was calculated and compared between different age groups and different diseases. ROC curve was constructed and area under the curve was calculated to find out cut-off values value for PSAD. Sensitivity, specificity and accuracy were calculated at the cut-off values.


RESULTS: Among 309 patients of median age was 68 years (IQR 43 – 75). There was a significant difference of PSAD in different age groups (p<0.001) and diseases like prostate carcinoma, benign prostatic hyperplasia and other prostatic disorders. PSAD had AUC of 0.878 at cut-off value of 0.135 ng/ml where sensitivity was 100%. A higher cut-off 0.20 ng/ml was suggested in younger age group as compared to the old age group where cut-off was found 0.135.


CONCLUSION: Using PSAD as part of evaluation profile for prostate lesion, number of unnecessary biopsies can be significantly decreased. PSAD cut-off to aid in decision of invasive prostate biopsy is suggested to be 0.135 ng/ml with close biochemical follow up afterwards.

Article Details

How to Cite
Haroon, Z., Q. Bashir, A. Haroon, and U. Khalid. “CUT-OFF VALUES OF PROSTATE SPECIFIC ANTIGEN DENSITY– AN EFFECTIVE SCREENING MARKER BEFORE PROSTATE BIOPSY”. KHYBER MEDICAL UNIVERSITY JOURNAL, Vol. 14, no. 1, Mar. 2022, doi:10.35845/kmuj.2022.21763.
Section
Original Articles

References

1. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2013;189(1 Suppl):S2-S11. https://doi.org/10.1016/j.juro.2012.11.014
2. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29(27):3669-76. https://doi.org/10.1200/jco.2011.34.9738
3. Kim HW, Ko YH, Kang SH, Lee JG. Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml. Korean J Urol 2011;52(3):166-71. https://doi.org/10.4111/kju.2011.52.3.166
4. Reis LO, Zani EL, Alonso JC, Simões FA, Rejowski RF, Ferreira U. Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study. Actas Urol Esp 2011;35(1):10-4. https://doi.org/10.1016/j.acuro.2010.06.011
5. Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, et. al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66(1):22-9. https://doi.org/10.1016/j.eururo.2014.03.002
6. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate specific antigen. Eur Urol 2014;65(4):809-15. https://doi.org/10.1016/j.eururo.2013.03.025
7. Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 2012;62(3):431-52. https://doi.org/10.1016/j.eururo.2012.05.044
8. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 2018;21(1):57-63. https://doi.org/10.1038/s41391-017-0024-7
9. Jue JS, Barboza MP, Prakash NS, Venkatramani V, Sinha VR, Pavan N, et al. Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy. Urology 2017;105:123-8. https://doi.org/10.1016/j.urology.2017.04.015
10. Martins ACP, Borelli- Bovo TJ, Reis RB, Paschoalin EL, Cologna AJ, Suaid HJ. Performance of PSA and of PSA density in the diagnosis of prostate carcinoma. Acta Cir Bras 2002;17(Suppl 3):7-11. https://doi.org/10.1590/S0102-86502002000900002
11. Snoek FJ. Looking back on 25 years of the PSAD study group. Diabet Med 2020;37(3):380-2. https://doi.org/10.1111/dme.14163
12. Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 2009;39(7):468-9. https://doi.org/10.1093/jjco/hyp077
13. Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, et al. The ability of prostate‐specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. Br J Urol Int 2012;110(1):36-42. https://doi.org/10.1111/j.1464-410x.2011.10681.x
14. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. Br J Urol Int 2013;111(5):753-60. https://doi.org/10.1111/j.1464-410x.2012.11611.x
15. Kosaka T, Mizuno R, Shinojima T, Miyajima A, Kikuchi E, Tanaka N, et al. The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years. Am J Clin Exp Urol 2014;2(4):332–6.
16. Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate Specific Antigen Density Correlates with Features of Prostate Cancer Aggressiveness. J Urol 2007;177(2):505-9. https://doi.org/10.1016/j.juro.2006.09.039
17. Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, et al. Prostate‐specific antigen vs prostate‐specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. Br J Urol Int 2012;110(11 Pt B):E494-9. https://doi.org/10.1111/j.1464-410x.2012.11182.x
18. Shahab AA, Soebadi DM, Djatisoesanto W, Hardjowijoto S, Soetojo S, Hakim L. Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer. Prostate Int 2013;1(1):23-30. https://doi.org/10.12954/pi.12003
19. Tsang CF, Lai TC, Lam W, Ho BS, Ng AT, Ma WK, et al. Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population? Prostate Int 2019;7(2):73-7. https://doi.org/10.1016/j.prnil.2018.03.002
20. Lin YR, Wei XH, Uhlman M, Lin XT, Wu SF, Diao PF, et al. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml-1 and 10.1–20.0 ng ml-1: a multicenter study. Asian J Androl 2015;17(3):503. https://doi.org/10.4103/1008-682x.142129
21. Yanai Y, Kosaka T, Hongo H, Matsumoto K, Shinojima T, Kikuchi E, et al. Evaluation of prostate specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA. Mol Clin Oncol 2018;9(6):656-60. https://doi.org/10.3892/mco.2018.1725
22. Teoh JY, Yuen SK, Tsu JH, Wong CK, Ho BS, Ng AT, et al. The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men. Asian J Androl 2017;19(1):113-16. https://doi.org/10.4103/1008-682x.167103